The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Hypogonadism Drug Market Research Report 2024
Synopsis
There are two drugs for treatment of hypogonadism, one is testosterone replacement therapy drug; The other is used for gonadotropin treatment, which aims to maintain the normal development of male secondary sexual characteristics and restore fertility.
Global Hypogonadism Drug market is projected to reach US$ 4902.8 million in 2029, increasing from US$ 3393 million in 2022, with the CAGR of 5.4% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Hypogonadism Drug market research.
Rising population and rising incidence and prevalence of chronic diseases such as diabetes and obesity drive the market growth. According to clinical studies, the testosterone levels of men aged 60-80 are 20% and 80% lower than those of young men, respectively. Hypogonadism is most common in men over the age of 60. In countries such as Japan, China, and the U.S., the demand for male hypogonadism treatment has surged due to rising geriatric population and surging infertility rates.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Hypogonadism Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Allergan
AbbVie
Endo Pharmaceuticals
Pfizer Inc.
Clarus Therapeutics, Inc.
Aytu BioScience, Inc.
Antares Pharma
Upsher-Smith Laboratories, Inc.
Beijing Shuanghe Pharmaceutical Co., Ltd
Tianjin Jinyao Amino Acid Co., Ltd
Shanghai General Pharmaceutical Co., Ltd
Tianjin Lisheng Pharmaceutical Co., Ltd
Chengde Jiulong Pharmaceutical Co., Ltd
Harbin Pharmaceutical Group
Shenyang Keda Pharmaceutical Co., Ltd
Zhejiang Xianju Pharmaceutical Co., Ltd
Segment by Type
Injection
Capsule
Segment by Application
Hospital
Pharmacy
Specialist Clinic
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Hypogonadism Drug report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
There are two drugs for treatment of hypogonadism, one is testosterone replacement therapy drug; The other is used for gonadotropin treatment, which aims to maintain the normal development of male secondary sexual characteristics and restore fertility.
Global Hypogonadism Drug market is projected to reach US$ 4902.8 million in 2029, increasing from US$ 3393 million in 2022, with the CAGR of 5.4% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Hypogonadism Drug market research.
Rising population and rising incidence and prevalence of chronic diseases such as diabetes and obesity drive the market growth. According to clinical studies, the testosterone levels of men aged 60-80 are 20% and 80% lower than those of young men, respectively. Hypogonadism is most common in men over the age of 60. In countries such as Japan, China, and the U.S., the demand for male hypogonadism treatment has surged due to rising geriatric population and surging infertility rates.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Hypogonadism Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Allergan
AbbVie
Endo Pharmaceuticals
Pfizer Inc.
Clarus Therapeutics, Inc.
Aytu BioScience, Inc.
Antares Pharma
Upsher-Smith Laboratories, Inc.
Beijing Shuanghe Pharmaceutical Co., Ltd
Tianjin Jinyao Amino Acid Co., Ltd
Shanghai General Pharmaceutical Co., Ltd
Tianjin Lisheng Pharmaceutical Co., Ltd
Chengde Jiulong Pharmaceutical Co., Ltd
Harbin Pharmaceutical Group
Shenyang Keda Pharmaceutical Co., Ltd
Zhejiang Xianju Pharmaceutical Co., Ltd
Segment by Type
Injection
Capsule
Segment by Application
Hospital
Pharmacy
Specialist Clinic
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Hypogonadism Drug report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Index1 Hypogonadism Drug Market Overview
1.1 Product Overview and Scope of Hypogonadism Drug
1.2 Hypogonadism Drug Segment by Type
1.2.1 Global Hypogonadism Drug Market Value Comparison by Type (2023-2029)
1.2.2 Injection
1.2.3 Capsule
1.3 Hypogonadism Drug Segment by Application
1.3.1 Global Hypogonadism Drug Market Value by Application: (2023-2029)
1.3.2 Hospital
1.3.3 Pharmacy
1.3.4 Specialist Clinic
1.3.5 Others
1.4 Global Hypogonadism Drug Market Size Estimates and Forecasts
1.4.1 Global Hypogonadism Drug Revenue 2018-2029
1.4.2 Global Hypogonadism Drug Sales 2018-2029
1.4.3 Global Hypogonadism Drug Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Hypogonadism Drug Market Competition by Manufacturers
2.1 Global Hypogonadism Drug Sales Market Share by Manufacturers (2018-2023)
2.2 Global Hypogonadism Drug Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Hypogonadism Drug Average Price by Manufacturers (2018-2023)
2.4 Global Hypogonadism Drug Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Hypogonadism Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Hypogonadism Drug, Product Type & Application
2.7 Hypogonadism Drug Market Competitive Situation and Trends
2.7.1 Hypogonadism Drug Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Hypogonadism Drug Players Market Share by Revenue
2.7.3 Global Hypogonadism Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Hypogonadism Drug Retrospective Market Scenario by Region
3.1 Global Hypogonadism Drug Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Hypogonadism Drug Global Hypogonadism Drug Sales by Region: 2018-2029
3.2.1 Global Hypogonadism Drug Sales by Region: 2018-2023
3.2.2 Global Hypogonadism Drug Sales by Region: 2024-2029
3.3 Global Hypogonadism Drug Global Hypogonadism Drug Revenue by Region: 2018-2029
3.3.1 Global Hypogonadism Drug Revenue by Region: 2018-2023
3.3.2 Global Hypogonadism Drug Revenue by Region: 2024-2029
3.4 North America Hypogonadism Drug Market Facts & Figures by Country
3.4.1 North America Hypogonadism Drug Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Hypogonadism Drug Sales by Country (2018-2029)
3.4.3 North America Hypogonadism Drug Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Hypogonadism Drug Market Facts & Figures by Country
3.5.1 Europe Hypogonadism Drug Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Hypogonadism Drug Sales by Country (2018-2029)
3.5.3 Europe Hypogonadism Drug Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Hypogonadism Drug Market Facts & Figures by Country
3.6.1 Asia Pacific Hypogonadism Drug Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Hypogonadism Drug Sales by Country (2018-2029)
3.6.3 Asia Pacific Hypogonadism Drug Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Hypogonadism Drug Market Facts & Figures by Country
3.7.1 Latin America Hypogonadism Drug Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Hypogonadism Drug Sales by Country (2018-2029)
3.7.3 Latin America Hypogonadism Drug Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Hypogonadism Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Hypogonadism Drug Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Hypogonadism Drug Sales by Country (2018-2029)
3.8.3 Middle East and Africa Hypogonadism Drug Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Hypogonadism Drug Sales by Type (2018-2029)
4.1.1 Global Hypogonadism Drug Sales by Type (2018-2023)
4.1.2 Global Hypogonadism Drug Sales by Type (2024-2029)
4.1.3 Global Hypogonadism Drug Sales Market Share by Type (2018-2029)
4.2 Global Hypogonadism Drug Revenue by Type (2018-2029)
4.2.1 Global Hypogonadism Drug Revenue by Type (2018-2023)
4.2.2 Global Hypogonadism Drug Revenue by Type (2024-2029)
4.2.3 Global Hypogonadism Drug Revenue Market Share by Type (2018-2029)
4.3 Global Hypogonadism Drug Price by Type (2018-2029)
5 Segment by Application
5.1 Global Hypogonadism Drug Sales by Application (2018-2029)
5.1.1 Global Hypogonadism Drug Sales by Application (2018-2023)
5.1.2 Global Hypogonadism Drug Sales by Application (2024-2029)
5.1.3 Global Hypogonadism Drug Sales Market Share by Application (2018-2029)
5.2 Global Hypogonadism Drug Revenue by Application (2018-2029)
5.2.1 Global Hypogonadism Drug Revenue by Application (2018-2023)
5.2.2 Global Hypogonadism Drug Revenue by Application (2024-2029)
5.2.3 Global Hypogonadism Drug Revenue Market Share by Application (2018-2029)
5.3 Global Hypogonadism Drug Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Allergan
6.1.1 Allergan Corporation Information
6.1.2 Allergan Description and Business Overview
6.1.3 Allergan Hypogonadism Drug Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Allergan Hypogonadism Drug Product Portfolio
6.1.5 Allergan Recent Developments/Updates
6.2 AbbVie
6.2.1 AbbVie Corporation Information
6.2.2 AbbVie Description and Business Overview
6.2.3 AbbVie Hypogonadism Drug Sales, Revenue and Gross Margin (2018-2023)
6.2.4 AbbVie Hypogonadism Drug Product Portfolio
6.2.5 AbbVie Recent Developments/Updates
6.3 Endo Pharmaceuticals
6.3.1 Endo Pharmaceuticals Corporation Information
6.3.2 Endo Pharmaceuticals Description and Business Overview
6.3.3 Endo Pharmaceuticals Hypogonadism Drug Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Endo Pharmaceuticals Hypogonadism Drug Product Portfolio
6.3.5 Endo Pharmaceuticals Recent Developments/Updates
6.4 Pfizer Inc.
6.4.1 Pfizer Inc. Corporation Information
6.4.2 Pfizer Inc. Description and Business Overview
6.4.3 Pfizer Inc. Hypogonadism Drug Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Pfizer Inc. Hypogonadism Drug Product Portfolio
6.4.5 Pfizer Inc. Recent Developments/Updates
6.5 Clarus Therapeutics, Inc.
6.5.1 Clarus Therapeutics, Inc. Corporation Information
6.5.2 Clarus Therapeutics, Inc. Description and Business Overview
6.5.3 Clarus Therapeutics, Inc. Hypogonadism Drug Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Clarus Therapeutics, Inc. Hypogonadism Drug Product Portfolio
6.5.5 Clarus Therapeutics, Inc. Recent Developments/Updates
6.6 Aytu BioScience, Inc.
6.6.1 Aytu BioScience, Inc. Corporation Information
6.6.2 Aytu BioScience, Inc. Description and Business Overview
6.6.3 Aytu BioScience, Inc. Hypogonadism Drug Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Aytu BioScience, Inc. Hypogonadism Drug Product Portfolio
6.6.5 Aytu BioScience, Inc. Recent Developments/Updates
6.7 Antares Pharma
6.6.1 Antares Pharma Corporation Information
6.6.2 Antares Pharma Description and Business Overview
6.6.3 Antares Pharma Hypogonadism Drug Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Antares Pharma Hypogonadism Drug Product Portfolio
6.7.5 Antares Pharma Recent Developments/Updates
6.8 Upsher-Smith Laboratories, Inc.
6.8.1 Upsher-Smith Laboratories, Inc. Corporation Information
6.8.2 Upsher-Smith Laboratories, Inc. Description and Business Overview
6.8.3 Upsher-Smith Laboratories, Inc. Hypogonadism Drug Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Upsher-Smith Laboratories, Inc. Hypogonadism Drug Product Portfolio
6.8.5 Upsher-Smith Laboratories, Inc. Recent Developments/Updates
6.9 Beijing Shuanghe Pharmaceutical Co., Ltd
6.9.1 Beijing Shuanghe Pharmaceutical Co., Ltd Corporation Information
6.9.2 Beijing Shuanghe Pharmaceutical Co., Ltd Description and Business Overview
6.9.3 Beijing Shuanghe Pharmaceutical Co., Ltd Hypogonadism Drug Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Beijing Shuanghe Pharmaceutical Co., Ltd Hypogonadism Drug Product Portfolio
6.9.5 Beijing Shuanghe Pharmaceutical Co., Ltd Recent Developments/Updates
6.10 Tianjin Jinyao Amino Acid Co., Ltd
6.10.1 Tianjin Jinyao Amino Acid Co., Ltd Corporation Information
6.10.2 Tianjin Jinyao Amino Acid Co., Ltd Description and Business Overview
6.10.3 Tianjin Jinyao Amino Acid Co., Ltd Hypogonadism Drug Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Tianjin Jinyao Amino Acid Co., Ltd Hypogonadism Drug Product Portfolio
6.10.5 Tianjin Jinyao Amino Acid Co., Ltd Recent Developments/Updates
6.11 Shanghai General Pharmaceutical Co., Ltd
6.11.1 Shanghai General Pharmaceutical Co., Ltd Corporation Information
6.11.2 Shanghai General Pharmaceutical Co., Ltd Hypogonadism Drug Description and Business Overview
6.11.3 Shanghai General Pharmaceutical Co., Ltd Hypogonadism Drug Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Shanghai General Pharmaceutical Co., Ltd Hypogonadism Drug Product Portfolio
6.11.5 Shanghai General Pharmaceutical Co., Ltd Recent Developments/Updates
6.12 Tianjin Lisheng Pharmaceutical Co., Ltd
6.12.1 Tianjin Lisheng Pharmaceutical Co., Ltd Corporation Information
6.12.2 Tianjin Lisheng Pharmaceutical Co., Ltd Hypogonadism Drug Description and Business Overview
6.12.3 Tianjin Lisheng Pharmaceutical Co., Ltd Hypogonadism Drug Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Tianjin Lisheng Pharmaceutical Co., Ltd Hypogonadism Drug Product Portfolio
6.12.5 Tianjin Lisheng Pharmaceutical Co., Ltd Recent Developments/Updates
6.13 Chengde Jiulong Pharmaceutical Co., Ltd
6.13.1 Chengde Jiulong Pharmaceutical Co., Ltd Corporation Information
6.13.2 Chengde Jiulong Pharmaceutical Co., Ltd Hypogonadism Drug Description and Business Overview
6.13.3 Chengde Jiulong Pharmaceutical Co., Ltd Hypogonadism Drug Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Chengde Jiulong Pharmaceutical Co., Ltd Hypogonadism Drug Product Portfolio
6.13.5 Chengde Jiulong Pharmaceutical Co., Ltd Recent Developments/Updates
6.14 Harbin Pharmaceutical Group
6.14.1 Harbin Pharmaceutical Group Corporation Information
6.14.2 Harbin Pharmaceutical Group Hypogonadism Drug Description and Business Overview
6.14.3 Harbin Pharmaceutical Group Hypogonadism Drug Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Harbin Pharmaceutical Group Hypogonadism Drug Product Portfolio
6.14.5 Harbin Pharmaceutical Group Recent Developments/Updates
6.15 Shenyang Keda Pharmaceutical Co., Ltd
6.15.1 Shenyang Keda Pharmaceutical Co., Ltd Corporation Information
6.15.2 Shenyang Keda Pharmaceutical Co., Ltd Hypogonadism Drug Description and Business Overview
6.15.3 Shenyang Keda Pharmaceutical Co., Ltd Hypogonadism Drug Sales, Revenue and Gross Margin (2018-2023)
6.15.4 Shenyang Keda Pharmaceutical Co., Ltd Hypogonadism Drug Product Portfolio
6.15.5 Shenyang Keda Pharmaceutical Co., Ltd Recent Developments/Updates
6.16 Zhejiang Xianju Pharmaceutical Co., Ltd
6.16.1 Zhejiang Xianju Pharmaceutical Co., Ltd Corporation Information
6.16.2 Zhejiang Xianju Pharmaceutical Co., Ltd Hypogonadism Drug Description and Business Overview
6.16.3 Zhejiang Xianju Pharmaceutical Co., Ltd Hypogonadism Drug Sales, Revenue and Gross Margin (2018-2023)
6.16.4 Zhejiang Xianju Pharmaceutical Co., Ltd Hypogonadism Drug Product Portfolio
6.16.5 Zhejiang Xianju Pharmaceutical Co., Ltd Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Hypogonadism Drug Industry Chain Analysis
7.2 Hypogonadism Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Hypogonadism Drug Production Mode & Process
7.4 Hypogonadism Drug Sales and Marketing
7.4.1 Hypogonadism Drug Sales Channels
7.4.2 Hypogonadism Drug Distributors
7.5 Hypogonadism Drug Customers
8 Hypogonadism Drug Market Dynamics
8.1 Hypogonadism Drug Industry Trends
8.2 Hypogonadism Drug Market Drivers
8.3 Hypogonadism Drug Market Challenges
8.4 Hypogonadism Drug Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
